Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of the cellular component interacted with F. nucleatum.

ABSTRACT: We incubated F. nucleatum lysates with biotinylated proteins from KRAS p.G12D, KRAS p.G13D and KRAS WT cells respectively. Subsequent western blot analysis showed that three candidate proteins from F. nucleatum might interact with KRAS p.G12D cells. The bands of interest were then submitted for mass spectrometry (MS) protein identification, which reported three proteins.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Fusobacterium Nucleatum Cti-1

SUBMITTER: Huiyuan Zhu

LAB HEAD: Huanlong Qin

PROVIDER: PXD048686 | Pride | 2024-01-25

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1912231_SG_Fn.wiff	Wiff
	1912231_SG_Fn.wiff.scan	Wiff
	IdentificationSummary.format1.xlsx	Xlsx

Items per page:

1 - 3 of 3

Similar Datasets

Idenfication the receptor on KRAS p.G12D cell that interact with FN1859

Project description:To capture the unknown receptors, we purified recombinant His-tagged FN1859 proteins from Escherichia coli and performed His-tag pull-down assays with WT, KRAS p.G13D and KRAS p.G12D cell lysates. Then the bands submitted for mass spectrometry (MS) protein identification.

2024-01-25 | PXD048684 | Pride

Mass spectrometry (MS) datasets of PURPL RNA pulldown samples in A375 cells

Project description:We performed PURPL RNA pulldown followed by MS analysis to identify purpl-interacting proteins in A375 cells.With high performance liquid chromatography-mass spectrometry (HPLC-MS), the binding protein of PURPL from RNA pull down was detected by removing non-specific protein which were binding with EGFP.

2022-02-16 | PXD028863 | Pride

LncRNA LINC01186 directly bingding proteins in Hepatocellular carcinoma

Project description:We conducted an RNA pulldown assay in Hepatocellular carcinoma cell line HepG2 using in vitro-transcribed full-length LINC01186 RNA accompanied with a control EGFP RNA. The specific binding proteins of LINC01186 was identified using high-performance liquid chromatography-mass spectrometry (HPLC-MS).

2022-07-23 | PXD031844 | Pride

EP300 promotes ferroptosis via HSPA5 acetylation in pancreatic cancer

Project description:Ferroptosis is a form of regulated cell death characterized by oxidative injury-induced lipid peroxidation. However, the detailed protein post-translational modification regulatory mechanism of ferroptosis remains largely unknown. Here, we report that E1A binding protein P300 (EP300) acetyltransferase promotes ferroptosis in human pancreatic ductal adenocarcinoma (PDAC) cells via the acetylation of heat shock protein family A (Hsp70) member 5 (HSPA5, also known as GRP78 or BIP) on the site of K353. Acetylated HSPA5 loses its ability to inhibit lipid peroxidation and subsequent ferroptotic cell death. Genetic or pharmacological inhibition of EP300-mediated HSPA5 acetylation on K353 increases PDAC cell resistance to ferroptosis. Moreover, histone deacetylase 6 (HDAC6) limits HSPA5 acetylation and subsequent ferroptosis.

2023-10-24 | PXD039998 | Pride

human, gastric cancer line, LC-MSMS

Project description:We also tested the downstream differentiation of protein expression between BGC823 Ctrl and BGC823 MIR137HG by IP target FUS following LC-MS/MS. And we selected several proteins related to tumor growth and metastasis to analyze further. String data showed that they might have more contact with each other. Western blot data showed that MET, CTNNB1 and RHOC were also co-expressed with the over-expression MIR137HG.

2022-08-12 | PXD031258 | Pride

the Interaction Proteome of Ribosomal 40S Components PNO1 and NOB1 Using TurboID Proximity Labeling Technology

Project description:Background: The ribosome assembly factors PNO1 and NOB1 play crucial roles in the maturation of the 40S ribosomal small subunit. TurboID is an efficient biotin ligase that can biotinylate proteins in proximity to the target protein and is widely used to study complex biological processes within cells.Here, we utilized this technology to investigate the complex interaction network of PNO1 and NOB1 within cells.

2024-06-08 | PXD052825 | Pride

CCT3 acts as upstream of YAP and TFCP2 to be a potential target and tumor biomarker in liver cancer

Project description:Recently, we've reported that pro-tumorigenic roles of YAP in liver cancer are indispensable of TFCP2 act as upstream to simultaneously control YAP.The aim of this study is to uncover such proteins and evaluate whether the candidates are potential YAP-associated therapeutic target and diagnostic marker Via mass spectrometry, CCT3 was identified to co-interact with YAP and TFCP2, and importantly.

2019-09-11 | PXD013143 | Pride

proteins pulled down by CREB, part 2

Project description:Hepatocarcinoma is the third leading cause of death in cancer in the world. In recent years, research on CREB in hepatocellular carcinoma has become a hotspot, so our research group wants to use the mass spectrometry analysis what proteins can bind with CREB, and then explore the links between CREB and hepatocellular carcinoma.

2019-11-08 | PXD008261 | Pride

Whole exome sequencing of human tumours and cell lines to investigate how ERBB2 and KRAS Alterations mediate response to EGFR inhibitors in early stage Gallbladder Cancer

Project description:Purpose: The uncommonness of gallbladder cancer in the developed world has contributed to the generally poor understanding of the disease. The development of new and effective treatment has been and continues to be a major public health imperative. Methods: We report mutational and copy number analysis of 44 predominantly early-staged gallbladder tumors and 5-gallbladder cancer cell lines by a combination of directed and whole exome sequencing at an average coverage of 100X and above. Using gallbladder cancer cell lines and xenograft mouse models we performed phospho-proteome array profiling, followed by an in-depth functional characterization. Results: We describe recurrent activating ERBB2 somatic mutation in 6 of 44 gallbladder primary tumors with an overall mutation frequency of 13%, along with KRAS activating mutations in 3 of 44 samples. Consistent with whole exome findings, a phospho-proteomic array profile of 49-tyrosine kinase revealed constitutive phosphorylation of ERBB2 and EGFR that were found to heterodimerize. We demonstrate that treatment with ERBB2-specific, EGFR-specific shRNA or with covalent EGFR family inhibitor BIBW-2992 inhibits transformation, survival, migration, invasion, and tumor forming characteristics of gallbladder cancer cells harboring wild type or KRAS (G13D) but not KRAS (G12V) mutation. Furthermore, we show in vivo reduction in tumor size is paralleled by a reduction in the amounts of phospho-ERK in KRAS (G13D) but not in KRAS (G12V) xenografts, validating the in vitro findings Conclusion: Findings from this study implicate ERBB2 as an important therapeutic target in early stage gallbladder cancer. We also present the first evidence that the presence of KRAS (G12V), but not KRAS (G13D) mutation, may preclude gallbladder cancer patients to respond to anti-EGFR treatment, similar to the clinical algorithm commonly practiced to opt for anti-EGFR treatment in colorectal cancer.

2018-12-29 | E-MTAB-6619 | biostudies-arrayexpress

Transcription profiling of human breast cell lines and one normal RNA sample

Project description:Total RNA from seven breast cell lines and one normal RNA samples was labelled using the Illumina TotalPrep RNA Amplification kit (Ambion) following manufacturer's instructions. 1.5 ug of biotin-labelled cRNA were used for each hybridisation on Sentrix Human-6 BeadChips (Illumina, San Diego, CA) following manufacturer's protocol.

2007-11-17 | E-TABM-194 | biostudies-arrayexpress